Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

NCT01048034 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Azacitidine
DRUG: Erythropoetin

Sponsor

Nordic MDS Group